NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer [Yahoo! Finance]
NovaBridge Biosciences - American Depositary Shares (NBP)
Company Research
Source: Yahoo! Finance
1L HER2-negative, metastatic gastric cancer patients, with 77% ORR observed at 8 mg/kg and 73% ORR observed at 12 mg/kg, across a wide range of PD-L1 and CLDN18.2 expression levels The median PFS was 16.9 months at 8 mg/kg; 12 mg/kg is immature with approximately 4-month shorter median follow-up; data will be updated in 2026 Six-month landmark PFS was 73% for 8 mg/kg, and 91% for 12 mg/kg cohorts Combination was well tolerated; safety is comparable to the current standard of care treatment Data demonstrate that givastomig is a potential best-in-class CLDN18.2 asset when added to 1L standard of care NovaBridge is on track to initiate enrollment in a global, randomized Phase 2 study, evaluating both doses against standard of care, in Q1 2026 Detailed Phase 1b dose expansion data are expected to be presented at a medical conference later in 2026 ROCKVILLE, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotec
Show less
Read more
Impact Snapshot
Event Time:
NBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBP alerts
High impacting NovaBridge Biosciences - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NBP
News
- Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsightPR Newswire
- Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsightPR Newswire
- Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic DiseasesGlobeNewswire
- NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric CancerGlobeNewswire
- NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026 [Yahoo! Finance]Yahoo! Finance
NBP
Sec Filings
- 1/6/26 - Form 6-K
- 1/2/26 - Form 144
- 12/18/25 - Form 144
- NBP's page on the SEC website